$1.65 -0.05 (%) Exelixis Inc - NASDAQ

Sep. 22, 2014 | 04:00 PM

Partner Headlines

  1. Stocks Hitting 52-Week Lows

    Benzinga | Sep. 15, 2014 | 10:09AM EST
  2. Equities, Commodities & Bonds Finish Lower On First Trading Day Of The Month

    Benzinga | Sep. 2, 2014 | 16:34PM EST
  3. Midday Losers From Tuesday, September 2

    Benzinga | Sep. 2, 2014 | 14:15PM EST
  4. Exelixis Shares Slide On Trial Results; Norwegian Cruise Line Surges

    Benzinga | Sep. 2, 2014 | 12:54PM EST
  5. Markets Mixed; Conn's Profit Misses Estimates

    Benzinga | Sep. 2, 2014 | 11:15AM EST
  6. Stocks Hitting 52-Week Lows

    Benzinga | Sep. 2, 2014 | 10:16AM EST
  7. Morning Market Losers

    Benzinga | Sep. 2, 2014 | 09:52AM EST
  8. Benzinga's Top Downgrades

    Benzinga | Sep. 2, 2014 | 08:53AM EST
  9. Stifel Nicolaus Downgrades Exelixis To Hold

    Benzinga | Sep. 2, 2014 | 08:24AM EST
  10. Stocks To Watch For September 2, 2014

    Benzinga | Sep. 2, 2014 | 04:05AM EST
  11. Exelixis Announces Results From COMET-1 Phase 3 Pivotal Trial Of Cabozantinib In Men W/ Metastatic Castration-Resistant Prostate Cancer; DId Not Meet Primary Endpoint

    Benzinga | Sep. 1, 2014 | 18:50PM EST
  12. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga | Jul. 14, 2014 | 15:06PM EST
  13. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga | Jul. 14, 2014 | 12:36PM EST
  14. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit Beats Street View

    Benzinga | Jul. 14, 2014 | 10:19AM EST
  15. Morning Market Movers

    Benzinga | Jul. 14, 2014 | 09:38AM EST
  16. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga | Jul. 14, 2014 | 09:05AM EST
  17. Benzinga's Top #PreMarket Gainers

    Benzinga | Jul. 14, 2014 | 08:10AM EST
  18. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga | Jun. 10, 2014 | 11:04AM EST
  19. Benzinga's Top #PreMarket Gainers

    Benzinga | May. 7, 2014 | 08:08AM EST
  20. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc. ...

    GuruFocus | May. 5, 2014 | 13:21PM EST
  21. Market Wrap For March 26: Markets Close Near Session Lows In Yet Another Volatile Trading Session

    Benzinga | Mar. 26, 2014 | 16:46PM EST
  22. Mid-Afternoon Market Update: Markets Turn Red as Dish Network Rises

    Benzinga | Mar. 26, 2014 | 15:46PM EST
  23. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis Shares Decline

    Benzinga | Mar. 26, 2014 | 12:28PM EST
  24. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat Q1 Forecast

    Benzinga | Mar. 26, 2014 | 10:24AM EST
  25. Stocks Hitting 52-Week Lows

    Benzinga | Mar. 26, 2014 | 10:22AM EST
  26. Morning Market Losers

    Benzinga | Mar. 26, 2014 | 09:53AM EST
  27. Benzinga's Top #PreMarket Losers

    Benzinga | Mar. 26, 2014 | 08:14AM EST
  28. Morning Market Movers

    Benzinga | Mar. 25, 2014 | 09:39AM EST
  29. US Stock Futures Rise Ahead Of Housing Data

    Benzinga | Mar. 25, 2014 | 07:30AM EST
  30. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga | Jan. 23, 2014 | 08:35AM EST
  31. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga | Dec. 17, 2013 | 15:45PM EST
  32. Exelixis Announces Promising Phase 1b Data for Cobimetinib in Combination with Vemurafenib at ECC 2013

    Benzinga | Sep. 28, 2013 | 09:21AM EST
  33. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga | Sep. 26, 2013 | 07:16AM EST
  34. Exelixis Announces Full Patient Enrollment for COMET-1 Phase 3 Trial

    Benzinga | Sep. 26, 2013 | 06:02AM EST
  35. US Stock Futures Up After Upbeat China Data

    Benzinga | Sep. 10, 2013 | 07:08AM EST
  36. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga | Sep. 10, 2013 | 06:03AM EST
  37. Exelixis Receives EMA Acceptance of Marketing Authorization App for COMETRIQ

    Benzinga | Nov. 29, 2012 | 09:32AM EST
  38. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 8, 2012 | 03:36AM EST
  39. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort in Metastatic Castration-Resistant Prostate Cancer

    Benzinga | Sep. 30, 2012 | 05:20AM EST
  40. First Solar, Sears Holdings Among Stocks Down on Above-average Volume Thursday

    FoxBusiness | Aug. 30, 2012 | 06:33AM EST
  41. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga | Aug. 29, 2012 | 11:02AM EST
  42. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity Financing Dilution

    Benzinga | Aug. 20, 2012 | 07:43AM EST
  43. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga | Aug. 9, 2012 | 07:03AM EST
  44. Exelixis, Universal Display Corporation Among Stocks Up on High Volume Thursday

    FoxBusiness | Aug. 9, 2012 | 06:33AM EST
  45. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New Drug Application for Cabozantinib November 9, 2012

    Benzinga | Aug. 9, 2012 | 02:51AM EST
  46. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter | Aug. 6, 2012 | 12:01PM EST
  47. Health Care Sector Wrap

    FoxBusiness | Aug. 6, 2012 | 10:44AM EST
  48. HCA Holdings, American Capital Mortgage Investment Crp Among Stocks Down on High Volume Monday

    FoxBusiness | Aug. 6, 2012 | 06:32AM EST
  49. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness | Aug. 6, 2012 | 04:31AM EST
  50. UPDATE: Exelixis Announces Proposed Convertible Debt Offering of $225M; Will Grant Underwriters Option to Buy Additional 3M Shares

    Benzinga | Aug. 6, 2012 | 02:45AM EST
Trading Center